Re: Farmas USA
INO vs. ACTC
En el foro de células madre comentaban que tienen que empezar a salir artículos como churros de la parte veterinaria con perros de ACTC y uno de los expertos lo compara con lo sucedido con INO:
"I witnessed the inflection point scenario with INOVIO (INO) .
I was a 2 years investor there were the company stayed in the range of 45c to 80c , then INO started the real move on their peer review document on July,24th "Potent hTERT DNA Cancer Vaccine". INO went from 1.26 to 3 dollars in few weeks and since then, INO is constantly pushing peer review documents that kept it a float between 2 and 3 dollars and it has under its belt low priced JV with Roche.I sold all of my shares in INO and moved some cash to ACTC and the rest invested in another new company.
I hope TLD peer review will trigger the same for ACTC to be 500M-700M market cap company until the new MSCs peer review studies will be pushed in timely manner to keep the company build up and sailing in the right direction. "
http://investorstemcell.com/forum/groups/ceasar-s-palace-premium-d922.htm
En un artículo sobre la "ciencia ficcción" del 2014:
"The previous year was witness to some remarkable advancements in additive manufacturing, including a 3D printed cybernetic ear that picks up radio frequencies outside the range of human hearing. Expect more of this in 2014, including 4D printing where objects "make themselves" by changing shape after they're printed. Also expect further progress in stem cell therapies (including trials conducted by Advanced Cell Technology involving the injection of stem-cell-derived retinal cells into the eyes of people with non-treatable degenerative blindness), gene therapies, and nano-devices implanted beneath the skin to stimulate muscles. In addition, we should also expect advancements in assistive devices, especially the thought-controlled exoskeleton and advanced prosthetics."
http://io9.com/these-are-the-science-stories-to-watch-for-in-2014-1493071188
Artículo en FOX que se hace eco de un estudio sobre células embrionarias, que son las de ACTC y posterior comentario en el foro:
"Suppression of the T cell response leads to rescue and repair by CD4 helper T cell pathways. This is tolerance of the immune system.
Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. This plays right into Lanza's eMSc dog trials. Since the gene for CTLA-4 is down regulated for lupus, MSand other diseases in autoimmune disease this could be a benefit and strategy of developing protection of Lanza's eMSC magic cells."
Como colofón, info ya conocida:
"The dry age-related macular degeneration market is 10 times the size of the wet macular degeneration market, and we see StemCells Inc. (STEM) and Advanced Cell Technology Inc. (OTC: ACTC) in a race in the dry macular degeneration space. Remember, it was macular degeneration that put Regeneron Pharmaceuticals (REGN) back on the map."
«Después de nada, o después de todo/ supe que todo no era más que nada.»
